Worldwide Clinical Trials (Worldwide), a privately held, leading global, full-service contract research organization, has announced the closing of its previously announced recapitalization that gives funds managed by Kohlberg & Company, LLC, a leading private equity firm with over 35 years of experience partnering with management and companies like Worldwide, a majority stake in the company. Middle-market private equity firm TJC, which has been Worldwide’s sole investor since 2007, retains a meaningful minority equity stake in the CRO.
Latham & Watkins LLP represented NB Capital Solutions in the transaction with a New York capital markets team led by partners Stelios Saffos, Pete Sluka, and Andrew Blumenthal, with associates Ian Lachow and Emma Gilmore. Advice was also provided on tax matters by Century City partner Pardis Zomorodi.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.From Legal Desire
Is your firm the one being cited, or the one being skipped?
We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.
Lawyers and firms: get featured on Legal Desire
Share your deals, lateral moves, firm news and insights with 1M+ monthly readers: founders, law firm partners, general counsel and practising lawyers across the US, UK, EU and GCC.
Get featuredSubmit a press releaseThe advising firms, the named deal team, the value and the parties, with every other announced deal by the same firms and lawyers. Open the deal record
